Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, and chair of the Miami Breast Cancer Conference, discusses the evolution of breast cancer treatment in recent years. Borgen shared his insight in an interview during the meeting.
Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.
Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.
Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.
Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.
Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.
Endocrine therapy can achieve tumor reduction for patients with ER-positive breast cancer, possibly avoiding the need for chemotherapy or even surgery in some patients; however, deciding how long to continue this therapy can be tricky.
The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer is a quantum leap toward precision oncology, as it codifies advanced knowledge of the role of biologic factors in cancer, and oncologists should now be using it.
With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.
The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.
The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.
Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.
Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.
Palbociclib (Ibrance) demonstrated significant efficacy in combination with letrozole (Femara) in the frontline setting of estrogen receptor-positive, HER2-negative, postmenopausal metastatic breast cancer.
Fabrice André, MD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the remaining questions with immunotherapy agents as potential therapy for patients with triple-negative breast cancer. Andre expanded on this in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.
William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the utilization of genetic testing in breast cancer to identify actionable results for patients.
The progression-free survival benefit for ribociclib in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer was sustained across patient subgroups, according to findings from the phase III MONALEESA-7 trial.
Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.
Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.
Gilberto Lopes, MD, discusses the global disparities occurring in lung cancer care and some of the steps that are being taken to better serve patients with the available and emerging therapeutic approaches.
Julie R. Brahmer, MD, discusses first-line immunotherapy, targeted therapies for molecularly driven tumors, and recently released guidelines for the treatment of patients with lung cancer.
Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.
Sarah B. Goldberg, MD, discusses testing for and treating resistance to EGFR TKI therapy in non-small cell lung cancer.
Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.
PARP inhibitor combination regimens have the potential to enhance the relatively modest benefit offered by several monotherapy approaches used for the treatment of patients with ovarian cancer.
Erdafitinib showed responses in more than one-third of patients with pretreated metastatic or unresectable FGFR alteration-positive urothelial carcinoma.
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses pelvic exenteration surgery for patients with gynecologic cancer.
Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.
Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.
